Erschienen in:
09.06.2020 | COVID-19 | Editorial
Zur Zeit gratis
How likely are COVID-19 interventions to benefit the sickest patients?
verfasst von:
Anders Perner, Bharath Kumar Tirupakuzhi Vijayaraghavan, Balasubramanian Venkatesh
Erschienen in:
Intensive Care Medicine
|
Ausgabe 7/2020
Einloggen, um Zugang zu erhalten
Excerpt
The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in more than 4.3 M infections and 297,000 deaths worldwide [
1]. It has placed an unprecedented demand on healthcare and overwhelmed the capacity of critical care services in some countries. The manifestations of COVID-19 vary from fever and mild upper respiratory tract symptoms to pneumonia, acute respiratory distress syndrome (ARDS), and multiple organ failure resulting in death [
2]. Worsening disease may be driven by increased viral load and hyper-inflammation in addition to increasing age and co-morbidities [
2]. Capitalising on this knowledge, several trials are underway testing the efficacy of anti-viral agents, anti-malarial agents, immune modulators, and angiotensin receptor blockers. …